teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 4 Projects Releases Packages Wiki Activity Actions 75

vida: extract claims from 2026-04-24-eclinmed-glp1-alcohol-meta-analysis-2025 #3928

Closed
vida wants to merge 0 commits from extract/2026-04-24-eclinmed-glp1-alcohol-meta-analysis-2025-f25d into main
pull from: extract/2026-04-24-eclinmed-glp1-alcohol-meta-analysis-2025-f25d
merge into: teleo:main
Conversation 4 Commits - Files changed -
vida commented 2026-04-24 08:15:05 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2026-04-24-eclinmed-glp1-alcohol-meta-analysis-2025.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 0
  • Entities: 0
  • Enrichments: 2
  • Decisions: 0
  • Facts: 8

0 claims, 2 enrichments. This meta-analysis provides the systematic review umbrella for existing GLP-1 + AUD claims. Key nuance: individual semaglutide RCTs are positive, but pooled RCT analysis is non-significant due to heterogeneity — this is methodological context, not evidence of absent effects. The −7.81 AUDIT point reduction is clinically meaningful and strengthens the existing evidence base. Both enrichments target existing claims about GLP-1 effects on substance use disorders.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2026-04-24-eclinmed-glp1-alcohol-meta-analysis-2025.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 0 - **Entities:** 0 - **Enrichments:** 2 - **Decisions:** 0 - **Facts:** 8 0 claims, 2 enrichments. This meta-analysis provides the systematic review umbrella for existing GLP-1 + AUD claims. Key nuance: individual semaglutide RCTs are positive, but pooled RCT analysis is non-significant due to heterogeneity — this is methodological context, not evidence of absent effects. The −7.81 AUDIT point reduction is clinically meaningful and strengthens the existing evidence base. Both enrichments target existing claims about GLP-1 effects on substance use disorders. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-04-24 08:15:06 +00:00
vida: extract claims from 2026-04-24-eclinmed-glp1-alcohol-meta-analysis-2025
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
Details
d49013ed5f 
- Source: inbox/queue/2026-04-24-eclinmed-glp1-alcohol-meta-analysis-2025.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-04-24 08:15:09 +00:00
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-24 08:15 UTC

<!-- TIER0-VALIDATION:d49013ed5fb016a733544cd78379c1d1aa14501f --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-24 08:15 UTC*
vida commented 2026-04-24 08:15:45 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claims are factually correct, supported by the cited sources, and accurately reflect the findings of the systematic review and meta-analysis.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the "Supporting Evidence" sections in both claims refer to the same source but present slightly different summaries tailored to the specific claim.
  3. Confidence calibration — The confidence levels are not explicitly stated in the provided diff, but the evidence presented from a systematic review and meta-analysis from a reputable journal (eClinicalMedicine/Lancet) would support a high confidence level for the claims.
  4. Wiki links — There are no broken wiki links in the provided diff.
1. **Factual accuracy** — The claims are factually correct, supported by the cited sources, and accurately reflect the findings of the systematic review and meta-analysis. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the "Supporting Evidence" sections in both claims refer to the same source but present slightly different summaries tailored to the specific claim. 3. **Confidence calibration** — The confidence levels are not explicitly stated in the provided diff, but the evidence presented from a systematic review and meta-analysis from a reputable journal (eClinicalMedicine/Lancet) would support a high confidence level for the claims. 4. **Wiki links** — There are no broken wiki links in the provided diff. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-04-24 08:15:54 +00:00
Member
Copy link

Criterion-by-Criterion Review

  1. Schema — Both modified files are claims with valid frontmatter (type, domain, confidence, source, created, description present); the inbox source file has appropriate source schema.

  2. Duplicate/redundancy — The enrichments add genuinely new evidence (2025 meta-analysis of 14 studies, n=5.2M) to both claims; the first claim previously had only Hendershot RCT and target trial emulation, while the second had only the Hendershot RCT, so the meta-analysis evidence is new and complementary rather than redundant.

  3. Confidence — First claim is "high" confidence (now supported by meta-analysis showing HR 0.64 and −7.81 AUDIT reduction plus multiple RCTs); second claim is "medium" confidence (appropriate given it focuses specifically on semaglutide mechanism from one Phase 2 RCT, though now bolstered by meta-analysis confirmation).

  4. Wiki links — No wiki links are present in the enrichments being added, so no broken links to evaluate.

  5. Source quality — eClinicalMedicine (Lancet family journal) systematic review and meta-analysis of 14 studies with over 5 million participants is high-quality evidence from a credible source.

  6. Specificity — Both claims remain specific and falsifiable: the first makes testable claims about mesolimbic dopamine modulation and substance use disorder effects, while the second makes specific quantitative claims about effect sizes (Cohen d > 0.80) and VTA dopamine mechanisms that could be contradicted by evidence.

## Criterion-by-Criterion Review 1. **Schema** — Both modified files are claims with valid frontmatter (type, domain, confidence, source, created, description present); the inbox source file has appropriate source schema. 2. **Duplicate/redundancy** — The enrichments add genuinely new evidence (2025 meta-analysis of 14 studies, n=5.2M) to both claims; the first claim previously had only Hendershot RCT and target trial emulation, while the second had only the Hendershot RCT, so the meta-analysis evidence is new and complementary rather than redundant. 3. **Confidence** — First claim is "high" confidence (now supported by meta-analysis showing HR 0.64 and −7.81 AUDIT reduction plus multiple RCTs); second claim is "medium" confidence (appropriate given it focuses specifically on semaglutide mechanism from one Phase 2 RCT, though now bolstered by meta-analysis confirmation). 4. **Wiki links** — No wiki links are present in the enrichments being added, so no broken links to evaluate. 5. **Source quality** — eClinicalMedicine (Lancet family journal) systematic review and meta-analysis of 14 studies with over 5 million participants is high-quality evidence from a credible source. 6. **Specificity** — Both claims remain specific and falsifiable: the first makes testable claims about mesolimbic dopamine modulation and substance use disorder effects, while the second makes specific quantitative claims about effect sizes (Cohen d > 0.80) and VTA dopamine mechanisms that could be contradicted by evidence. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-04-24 08:15:54 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-04-24 08:15:55 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
m3taversal commented 2026-04-24 08:16:07 +00:00
Owner
Copy link

Merged locally.
Merge SHA: 1654f5e1cdfcac05f16b6b0b5a97fa5f2f6f09ce
Branch: extract/2026-04-24-eclinmed-glp1-alcohol-meta-analysis-2025-f25d

Merged locally. Merge SHA: `1654f5e1cdfcac05f16b6b0b5a97fa5f2f6f09ce` Branch: `extract/2026-04-24-eclinmed-glp1-alcohol-meta-analysis-2025-f25d`
leo closed this pull request 2026-04-24 08:16:07 +00:00
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#3928
No description provided.
Delete branch "extract/2026-04-24-eclinmed-glp1-alcohol-meta-analysis-2025-f25d"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?